ANPCF News and Press, Angle From 06/09/25

GUILDFORD, SURREY / ACCESS Newswire / June 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report and Financi...

GUILDFORD, UNITED KINGDOM / ACCESS Newswire / June 6, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that Non-Executive Director, Brian...

Notice of Preliminary Results and Webcast GUILDFORD, SURREY / ACCESS Newswire / May 23, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical onco...

UPDATE ON ASTRAZENECA ASSAY DEVELOPMENT PROJECTS AND SUCCESSFUL COMPLETION OF EISAI CONTRACT Development of both the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay successfully completed for AstraZeneca Results of Eisai Phase 2 pilot study supports th...

NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing platform Findings in lung cancer show that CTCs can provide additional biomarkers not found in ctDNA from single blood sample ANGLE invited to present data at EACR-Illumina webinar on 6 February 2025 ...

CLINICAL TRIAL POWERED BY PARSORTIX SYSTEM PROVIDES FIRST-IN-CLASS data FOR NOVEL APPROACH TO CANCER treatment Parsortix system used to identify patients with highly metastatic CTC clusters for targeted treatment New treatment strategy provides 'uncharted opportunity' to target metastas...